AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-699-7855
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions
What is AzurRx BioPharma's stock symbol?
AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."
What price target have analysts set for AZRX?
5 brokers have issued 12 month target prices for AzurRx BioPharma's shares. Their predictions range from $5.00 to $10.50. On average, they expect AzurRx BioPharma's share price to reach $7.50 in the next year. This suggests a possible upside of 231.9% from the stock's current price. View Analyst Price Targets for AzurRx BioPharma.
What is the consensus analysts' recommendation for AzurRx BioPharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AzurRx BioPharma.
What are Wall Street analysts saying about AzurRx BioPharma stock?
Here are some recent quotes from research analysts about AzurRx BioPharma stock:
- 1. Maxim Group analysts commented, "We are initiating coverage of Buy rating and a $5 price target. The company’s lead candidate is MS1819-SD, an oral, non-animal derived, recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) and chronic pancreatitis (CP)." (2/14/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a discounted cash flow-based asset value of $115M for MS1819, using a 15% discount rate and 2% terminal growth rate, with 40% probability of success." (8/17/2018)
Has AzurRx BioPharma been receiving favorable news coverage?
News headlines about AZRX stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AzurRx BioPharma earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of AzurRx BioPharma's key competitors?
Some companies that are related to AzurRx BioPharma include CytoDyn (CYDY), PhaseBio Pharmaceuticals (PHAS), Chiasma (CHMA), Humanigen (HGEN), AgeX Therapeutics (AGE), China SXT Pharmaceuticals (SXTC), ASLAN PHARMACEU/ADR (ASLN), Newron Pharmaceuticals (NWPHF), Sierra Oncology (SRRA), Unum Therapeutics (UMRX), Galmed Pharmaceuticals (GLMD), Aptinyx (APTX), Harrow Health (HROW), Correvio Pharma (CORV) and Eton Pharmaceuticals (ETON).
What other stocks do shareholders of AzurRx BioPharma own?
Who are AzurRx BioPharma's key executives?
AzurRx BioPharma's management team includes the folowing people:
- Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)
- Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)
- Mr. Daniel Dupret, Chief Scientific Officer (Age 63)
- Dr. Mathieu Schué Ph.D., Head of Laboratory
- Dr. James E. Pennington, Chief Medical Officer (Age 76)
When did AzurRx BioPharma IPO?
(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.
Who are AzurRx BioPharma's major shareholders?
AzurRx BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (4.11%). Company insiders that own AzurRx BioPharma stock include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor, Maged Shenouda and Pelican Partners Llc. View Institutional Ownership Trends for AzurRx BioPharma.
Which institutional investors are buying AzurRx BioPharma stock?
AZRX stock was purchased by a variety of institutional investors in the last quarter, including 683 Capital Management LLC. Company insiders that have bought AzurRx BioPharma stock in the last two years include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor and Maged Shenouda. View Insider Buying and Selling for AzurRx BioPharma.
How do I buy shares of AzurRx BioPharma?
Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AzurRx BioPharma's stock price today?
One share of AZRX stock can currently be purchased for approximately $2.26.
How big of a company is AzurRx BioPharma?
AzurRx BioPharma has a market capitalization of $38.28 million.
What is AzurRx BioPharma's official website?
How can I contact AzurRx BioPharma?
AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]
MarketBeat Community Rating for AzurRx BioPharma (NASDAQ AZRX)
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
